[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-stroke-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-stroke-acute":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,41,61,84,110,141,168,193,225,244,269,296,325,355,381,406,427,447,474,495,527,552,575,596,622],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100651597","phase-4-lumbrokinase-vs-placebo-in-moderate-to-severe-ischemic-stroke-100651597",false,"NCT07763405","Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke","Efficacy and Safety of Lumbrokinase Versus Placebo in Moderate-to-Severe Ischemic Stroke: A Multicenter, Randomized, Double-Blind Clinical Trial","Inclusion Criteria:\n\n* Age 18-80 years;\n* Acute ischemic stroke confirmed by CT or MRI;\n* Baseline NIHSS score 4-20 at enrollment;\n* Good prestroke functional status (mRS ≤1);\n* Randomization within 24 hours of last known well;\n* Written informed consent provided by the participant or legal representative.\n\nExclusion Criteria:\n\n* Received or planned intravenous thrombolysis or endovascular treatment after stroke onset;\n* Cardioembolic stroke (atrial fibrillation, heart valve replacement, atrial myxoma, endocarditis, etc.);\n* Other causative etiologies of stroke (aortic dissection, cervico-cerebral arterial dissection, vasculitis, vascular malformation, moyamoya disease\u002Fsyndrome, fibromuscular dysplasia, etc.);\n* Non-vascular neurological diseases (intracranial tumor, multiple sclerosis, etc.);\n* Accompanying hemorrhagic transformation of infarction;\n* Concomitant use of other fibrinolytic therapy (e.g., urokinase, batroxobin, snake-venom preparations) or anticoagulant therapy (e.g., argatroban, rivaroxaban, dabigatran);\n* Severe hepatic insufficiency (ALT or AST \\>2 × upper limit of normal) or renal insufficiency (creatinine \\>1.5 × ULN or eGFR \\\u003C40 mL\u002Fmin\u002F1.73 m²), or coagulopathy, or systemic bleeding, or thrombocytopenia (\\\u003C100×10⁹\u002FL);\n* History of intracranial hemorrhage (e.g., intracerebral hemorrhage or subarachnoid hemorrhage);\n* Bleeding diathesis or major surgery within 90 days (gastrointestinal bleeding, hemoptysis, etc.);\n* Hypersensitivity to lumbrokinase or aspirin;\n* Planned surgery or vascular reconstruction within 90 days that may require study-drug interruption;\n* History of malignancy or aneurysm (including intracranial or peripheral aneurysm);\n* Received lumbrokinase or other fibrinolytic therapy within 14 days prior to randomization;\n* Pregnancy or lactation;\n* Participation in another clinical trial;\n* Prior neurological or psychiatric disease that would interfere with neurological assessment;\n* Expected survival less than 90 days;\n* Expected inability to complete follow-up.","ALL","18 Years","80 Years",{"count":21,"type":22},1196,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","LUMEN is a multicenter, randomized, double-blind, placebo-controlled superiority trial designed to evaluate whether oral lumbrokinase enteric-coated capsules combined with aspirin improve functional outcomes compared with aspirin alone in patients with moderate-to-severe acute ischemic stroke. Eligible adults aged 18-80 years with a baseline NIHSS score of 4-20, prestroke mRS ≤1, and onset within 24 hours are randomly assigned 1:1 to receive either lumbrokinase (600,000 IU, three times daily for 28 days) plus aspirin 100 mg daily for 90 days, or matching placebo plus aspirin 100 mg daily for 90 days. All participants receive standard medical care according to guidelines. The primary efficacy endpoint is the proportion of patients achieving an excellent functional outcome (modified Rankin Scale score 0-1) at 90 days. The primary safety endpoint is the incidence of severe or moderate bleeding (GUSTO definition) within 90 days.",[28],"Ischemic Stroke, Acute","NOT_YET_RECRUITING","2026-08-10",{"date":32,"type":33},"2026-08-13","ACTUAL",{"date":35,"type":22},"2026-11-01",{"date":37,"type":22},"2028-12-31",{"name":39,"class":40},"Xinqiao Hospital of Chongqing","OTHER",{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":60},"100651396","phase-4-tirofiban-combined-with-aspirin-in-moderate-ischemic-stroke-100651396","NCT07760922","Tirofiban Combined With Aspirin in Moderate Ischemic Stroke","Efficacy and Safety of Tirofiban Combined With Aspirin in Moderate Ischemic Stroke: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Acute ischemic stroke; time from last known well to randomization ≤ 24 hours;\n3. Pre-randomization NIHSS score 4-10, with at least one of item 5 (upper limb) or item 6 (lower limb) ≥ 1;\n4. Pre-stroke modified Rankin Scale (mRS) ≤ 1;\n5. Written informed consent provided by the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT or MRI;\n2. Has received or is planned to receive reperfusion therapy (thrombolysis or endovascular treatment);\n3. Any definite cardioembolic source: chronic\u002Fparoxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction \\\u003C 30%;\n4. Definite indication for anticoagulation (atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism);\n5. Severe systemic disease (e.g., severe infection, severe hepatic or renal dysfunction);\n6. Allergy to tirofiban and\u002For aspirin;\n7. History of intracranial hemorrhage;\n8. Planned use of NSAIDs affecting platelet function;\n9. Gastrointestinal bleeding or major surgery within the past 3 months;\n10. Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months;\n11. Planned surgery or intervention requiring discontinuation of antiplatelet therapy;\n12. Stroke caused by angiography or surgery;\n13. Prior non-atherosclerotic arterial disease, including moyamoya disease, arterial dissection, fibromuscular dysplasia;\n14. Other structural brain disease (vascular malformation, tumor, abscess, multiple sclerosis, etc.) confirmed by CT\u002FMRI;\n15. Pregnancy or lactation;\n16. Prior neurologic or psychiatric disease that would interfere with neurologic assessment;\n17. Participation in another clinical trial;\n18. Advanced disease with expected survival \\\u003C 6 months;\n19. Expected inability to complete follow-up.",{"count":49,"type":22},1168,[25],"Ischemic stroke accounts for the majority of stroke cases in China, and moderate ischemic stroke (NIHSS 4-10) carries a high risk of early neurologic deterioration (END) and long-term disability. Although intensified antiplatelet strategies reduce END, they have not consistently improved long-term functional outcome. Tirofiban, a selective glycoprotein IIb\u002FIIIa receptor inhibitor, has shown a clinically meaningful trend toward better 90-day functional outcome (mRS 0-1) in prior tirofiban trials, but existing sample sizes were underpowered to detect this difference.\n\nTAMIS is a multicenter, randomized, double-blind, placebo-controlled superiority trial in patients with acute moderate ischemic stroke (NIHSS 4-10) within 24 hours of last known well. Eligible patients are randomized 1:1 to tirofiban plus aspirin versus placebo plus aspirin, both on a background of guideline-based standard medical care. The primary efficacy endpoint is the proportion of patients with an excellent functional outcome (mRS 0-1) at 90 days. The primary safety endpoint is symptomatic intracranial hemorrhage within 48 (±12) hours by the Heidelberg criteria.",[28],"2026-08-07",{"date":55,"type":33},"2026-08-12",{"date":57,"type":22},"2026-10-01",{"date":37,"type":22},{"name":39,"class":40},5,{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":83},"100622641","a-trial-of-adacolumn-on-cerebral-edema-after-anterior-circulation-ischemic-stroke-100622641","NCT07386262","A Trial of Adacolumn on Cerebral Edema After Anterior Circulation Ischemic Stroke","Efficacy and Safety of the Adacolumn® Granulocyte and Monocyte\u002FMacrophage Apheresis Device for Cerebral Edema After Acute Anterior Circulation Occlusive Cerebral Infarction: A Prospective, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. A clinical diagnosis of acute ischemic stroke;\n3. Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) determined by MRA or CTA or DSA;\n4. NIHSS score ≥10 at screening;\n5. Pre-stroke mRS score \\\u003C2 (independent in all activities of daily living);\n6. Time from stroke onset to initiation of the first Adacolumn treatment is ≤24 hours, stroke onset is defined as the last time the patient was known to be at their neurological baseline (wake-up strokes qualify if within this time window);\n7. All endovascular thrombectomy and\u002For intravenous thrombolysis must strictly adhere to the \"2024 Chinese Stroke Association Guidelines for Reperfusion Therapy in Acute Ischemic Stroke\" and the latest prescribing information regarding indications, contraindications, and procedural standards;\n8. Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Decompressive craniectomy performed before enrollment or between enrollment and initiation of study treatment;\n2. After endovascular thrombectomy: extensive contrast extravasation (diffuse subarachnoid high density or parenchymal high density not consistent with hematoma), new subarachnoid hemorrhage（SAH）, or symptomatic intracranial hemorrhage (sICH);\n3. Large-vessel occlusion is attributed to other determined etiologies per TOAST classification, such as tumor-related, dissection-related, or other clearly identifiable non-LAA\u002Fnon-CE causes.\n4. Clinical signs of brain herniation, such as unilateral or bilateral fixed dilated pupils and\u002For other loss of brainstem reflexes attributable to cerebral edema or herniation in the investigator's opinion;\n5. Intracranial lesions conferring markedly increased bleeding risk (known brain tumor, arteriovenous malformation, aneurysm);\n6. Inability to undergo MRI;\n7. Absolute neutrophil count \\\u003C1.5×10⁹\u002FL or \\>15×10⁹\u002FL\n8. Absolute monocyte count \\> 1.0 ×10⁹\u002FL;\n9. Red blood cells \\\u003C3.0×10¹²\u002FL ;\n10. Active internal bleeding or bleeding tendency (such as platelet count \\\u003C100×10⁹\u002FL, INR \\>1.7, PT \\>15 seconds);\n11. Marked hypercoagulability (fibrinogen \\>700 mg\u002FdL);\n12. Intracranial or spinal surgery or severe head trauma within the past 3 months;\n13. Refractory hypertension (persistent systolic blood pressure \\>185 mmHg or diastolic \\>110 mmHg);\n14. Known allergy to components of the blood purification system (including adsorption membrane, anticoagulants);\n15. Acute ST-segment elevation myocardial infarction and\u002For acute decompensated heart failure and\u002For corrected QT interval \\>520 ms and\u002For history of cardiac arrest within the past 6 months(pulseless electrical activity, ventricular tachycardia, ventricular fibrillation, or asystole);\n16. Body temperature \\>38°C or active infection;\n17. Active autoimmune disease or immunodeficiency;\n18. Participation in another interventional clinical trial within the past 30 days;\n19. Any other condition deemed unsuitable for participation by the investigator.",{"count":69,"type":22},10,[71],"NA","The primary objective is to investigate whether treatment with Adacolumn can ameliorate the progression of cerebral edema within 72 hours in patients with anterior circulation ischemic stroke. The secondary objective is to explore if Adacolumn could improve acute neurologic status, functional outcomes, treatment requirements and safety in patients with anterior circulation ischemic stroke.",[74,28,75,76],"Cerebral Edema","Malignant Cerebral Edema","Anterior Circulation Brain Infarction","2026-08-04",{"date":53,"type":33},{"date":30,"type":22},{"date":37,"type":22},{"name":82,"class":40},"Second Affiliated Hospital, Zhejiang University, School of Medicine",1,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":60},"100550097","mystroke-for-stroke-survivors-and-caregivers-100550097","NCT06442631","MyStroke for Stroke Survivors and Caregivers","An Individualized Video-based Stroke Education Platform for Stroke Survivors and Caregivers","Inclusion Criteria:\n\n* At least 18 years old\n* Admitted to hospital with clinical diagnosis of acute ischemic stroke (imaging confirmation not required)\n* Stroke symptom onset within 30 days of enrollment\n* Being discharged to either home or an acute rehabilitation facility\n* Access to internet enabled device (smartphone, tablet, computer)\n* Fluent in either English or Spanish (does not need to be native or primary language)\n* Willingness and ability to sign informed consent\n\nExclusion Criteria:\n\n* Severe aphasia (score of ≥2 on NIHSS item 9)\n* Ischemic stroke that is attributed to a surgical procedure\n* Resides in a skilled nursing facility prior to admission\n* Being discharged to skilled nursing facility or long-term acute care facility\n* Unwillingness or inability to participate in remote\u002Fvirtual study visits\n* A terminal or advanced condition that raises the possibility the subject may not survive 90 days\n* Any other illness or condition that the investigator feels would pose a hazard to the subject from participation in the study",{"count":92,"type":22},690,[71],"The goal of this multicenter randomized trial is to evaluate the impact of a personalized video-based stroke education platform on patient-centered and health system-centered outcomes. The main questions this study aims to address are:\n\n1. Does a personalized, video-based educational platform improve stroke knowledge?\n2. Does a personalized, video-based educational platform reduce post-discharge health system utilization?\n3. Do different strategies of nudging improve engagement with educational material after hospital discharge?\n\nIn order to determine the effect of this personalized stroke education strategy, researchers will compare subjects who receive standard stroke education with those who receive the personalized stroke education platform in addition to standard standard education. Patient knowledge will be assessed 90-days after discharge. Study participants will include both stroke patients and caregivers, who will:\n\n1. Receive standard education during the stroke hospitalization\n2. Complete a survey on the day of hospital discharge to assess their baseline knowledge.\n3. Half of the subjects will be randomly assigned to also receive access to the personalized stroke education platform on the day of discharge.\n4. All subjects will complete two follow-up study visits (7 and 90 days after discharge) in order to complete surveys.",[96,28],"Stroke, Acute",[98,99,100],"stroke education","ischemic stroke","stroke knowledge","2026-07-29",{"date":103,"type":33},"2026-07-31",{"date":105,"type":22},"2026-08-01",{"date":107,"type":22},"2030-03-01",{"name":109,"class":40},"University of Pennsylvania",{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":137,"leadSponsor":139,"locationsCount":83},"100649095","benson-relaxation-for-anxiety-and-depression-after-stroke-100649095","NCT07731282","Benson Relaxation for Anxiety and Depression After Stroke","Short-term Effects of Benson Relaxation Technique on Anxiety, Depression, and Prefrontal Cortical Function in Patients With Acute Ischemic Stroke: A Randomized Controlled Trial","BRT-Stroke","Inclusion Criteria:\n\n* Meets the diagnostic criteria for stroke set by the Neurology Branch of the Chinese Medical Association, and is confirmed as ischemic stroke based on CT or MRI examination results.\n\n  * In the acute stage of stroke (7-14 days after onset) ③ Age ≥ 18 years old ④ Clear consciousness, stable condition, and able to communicate effectively ⑤ Hospital Anxiety and Depression Scale (HADS) score: HADS-A ≥ 8 points or HADS-D ≥ 8 points (or both ≥ 8 points) ⑥ Voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Combined with severe aphasia, visual and auditory impairments, unable to cooperate with intervention and assessment\n\n  * Combined with severe dysfunction of organs such as the heart, liver, and kidneys or malignant tumors ③ Has a clear history of mental illness or has been taking anti-psychotic drugs for a long time ④ Is currently participating in other clinical intervention studies",true,{"count":120,"type":22},74,[71],"This study tests whether Benson Relaxation Technique (BRT), a simple mind-body relaxation method, can help reduce anxiety and depression in patients who had an ischemic stroke 7-14 days ago. Patients will be randomly assigned to either the BRT group (receiving 20-minute relaxation sessions twice daily for 2 weeks) or a control group (receiving health education sessions of the same duration). We will measure anxiety and depression using standard questionnaires, and use near-infrared brain imaging to see if BRT changes brain activity in the prefrontal cortex. The goal is to find a safe, non-drug way to improve mood in early stroke recovery.",[28,124,125],"Post-stroke Anxiety","Post-stroke Depression",[127,128,129,130,131,132],"Benson Relaxation Technique","Stroke","Anxiety","Functional Near-Infrared Spectroscopy","Nursing Intervention","Randomized Controlled Trial","2026-07-23",{"date":135,"type":33},"2026-07-28",{"date":133,"type":22},{"date":138,"type":22},"2026-10-31",{"name":140,"class":40},"Geng Nannan",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100617916","phase-3-single-bolus-non-immunogenic-staphylokinase-in-patients-with-acute-ischemic-stroke-within-45-24-hours-of-symptom-onset-100617916","NCT07324837","Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset","A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of the Recombinant Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset (FRIDA-CT)","FRIDA-CT","Inclusion Criteria:\n\n1. Men and women aged 18 years and over;\n2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to \"last-seen normal time\";\n3. Pre-stroke modified Rankin scale (mRS) score≤1;\n4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT\u002FMRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;\n5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume \\\u003C70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;\n6. Alberta Stroke Program Early CT score (ASPECTS) \\> 6;\n7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);\n8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;\n9. Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n1. Acute ischemic stroke within 4,5 h after symptom onset;\n2. Intended to proceed to endovascular treatment;\n3. Known hypersensitivity to the non-immunogenic staphylokinase;\n4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;\n5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;\n6. Blood glucose \\\u003C2.8 or \\>22.2 mmol\u002FL (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);\n7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;\n8. Subarachnoid hemorrhage;\n9. Major bleeding currently or within the past 6 months;\n10. Surgery on the brain or spinal cord in the last 2 months;\n11. Punctures of non-compressible arteries and veins in the last 7 days;\n12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;\n13. Platelet count below 100,000\u002Fmm3;\n14. Previous stroke or severe traumatic brain injury within 3 months;\n15. Unable to perform CT or MRI;\n16. History of hemorrhagic stroke or stroke of unspecified genesis;\n17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);\n18. Concomitant use of indirect oral anticoagulants (warfarin) with INR \\> 1.7;\n19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;\n20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).\n21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;\n22. Acute pancreatitis;\n23. Bacterial endocarditis, pericarditis;\n24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;\n25. Cancer with an increased risk of bleeding;\n26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;\n27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);\n28. Hemorrhagic diathesis, including renal and hepatic failure;\n29. Data on bleeding or acute trauma (fracture) at the time of examination;\n30. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.",{"count":150,"type":22},990,[152],"PHASE3","Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC \"SuperGene\", Russia) or placebo.",[28],[156],"Ischemic Stroke","RECRUITING","2026-07-22",{"date":133,"type":33},{"date":161,"type":33},"2026-06-09",{"date":163,"type":22},"2029-01-01",{"name":165,"class":166},"Supergene, LLC","INDUSTRY",22,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100648342","phase-4-telestroke-guided-thrombolysis-for-acute-ischemic-stroke-in-oman-100648342","NCT07721129","TeleStroke-Guided Thrombolysis for Acute Ischemic Stroke in Oman","Thrombolysis for Acute Ischemic Stroke Facilitated by TeleStroke: Oman TeleStroke Initiative","Inclusion Criteria:\n\n* Age \\>18 years. Acute neurologic deficits due to cerebral ischemia\u002Finfarction. Clearly defined onset with duration from stroke onset of \\\u003C4.5 hours. Significant neurological deficit (usually NIHSS score of 4-25).\n\nExclusion Criteria:\n\n* CT brain shows showing evidence of intracranial hemorrhage\n* CT brain showing acute or subacute infarct of size about \\>1\u002F3 Middle Cerebral Artery territory.\n* Arterial puncture at non compressible site in previous 7 days\n* History of previous intracranial hemorrhage.\n* Intracranial neoplasm, AV malformation, or aneurysm\n* Recent head injury OR intracranial or intraspinal surgery in last 3 mo.\n* Persistent Elevated BP \\>185\u002F110 mm Hg despite treatment.\n* Active ongoing internal bleeding.\n* Platelet count \\\u003C100 000\u002Fmm3.\n* Current use of NOACs OR warfarin with INR \\>1.7 OR Inj.Enoxaparin\u002FHeparin in therapeutic dose\n* Blood glucose concentration \\\u003C2.7mmol\u002FL (\\\u003C50mg\u002Fdl).\n\nRelative contraindications: (may consider IV alteplase on individual evaluation).\n\n* Seizure at onset with post ictal residual neurological deficit.\n* Signs of mild stroke in isolation or rapidly improving symptoms.\n* Pregnancy.\n* Recent GI or UT hemorrhage within the last 21 days.\n* Recent MI within previous 3 months (to exclude anterolateral infarct \u002F STEMI)",{"count":176,"type":22},200,[25],"The goal of this study is to establish and examine the efficacy of using a Telestroke network in Oman to facilitate using emergent thrombolysis for patients with acute ischemic stroke encountered in selected peripheral hospitals. It is proposed to establish a TeleStroke network involving two central hospitals in Muscat linked to three to five peripheral hospitals in Oman which currently have access to CT scans and basic infrastructure for management of AIS patients- but do not have a Neurology service. Selected staff from Internal Medicine\u002FEmergency Medicine departments, Nursing, Technical service and support staffs will be trained in the process of assessment and management of AIS patients including the use of IV alteplase or tenecteplase. They will also be trained in timely access of a Neurologist on call at the central hospital(s) using a TeleStroke network. The Neurologist would conduct a Telestroke based clinical assessment of the AIS patient, review imaging and laboratory results in a timely manner and advice the medical team at the peripheral hospital regarding administration of IV alteplase\u002Ftenecteplase. The main purpose of such consultation would be to recognize eligible patients for administration of IV thrombolysis safely at the earliest opportunity within 4.5 hours, leading to increased rates of such thrombolysis with expected improved outcomes. Outcomes would be compared among 100 patients with AIS managed across these 5 hospitals prior to initiation of the practice of thrombolysis and at least 100 patients treated each with IV alteplase using TeleStroke Consultation with Neurologist. Demonstration of efficacy of TeleStroke based stroke thrombolysis would lead to effective implementation of this practice in Oman.",[28,156],[128,181,182,183,184],"Acute Ischemic Stroke","Thrombolysis","Telestroke","Telemedicine","2026-07-19",{"date":158,"type":33},{"date":105,"type":22},{"date":189,"type":22},"2027-03-30",{"name":191,"class":192},"Oman Ministry of Health","OTHER_GOV",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":211,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100646451","phase-3-tegoprazan-for-prevention-of-gastrointestinal-complication-in-ischemic-stroke-patients-on-antiplatelet-therapy-tegostroke-100646451","NCT07687706","Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)","TegoStroke","Inclusion Criteria:\n\n1. Age 19 years or older.\n2. Hospitalization for acute ischemic stroke or transient ischemic attack, with antiplatelet therapy initiated for the first time, expected to continue for at least 6 months at the treating physician's discretion per relevant stroke guidelines, and within 4 weeks of the first antiplatelet dose at the time of randomization.\n3. Written informed consent provided by the participant or a legally authorized representative.\n4. Ability and willingness to understand the study procedures described in the consent form and to comply with the study protocol.\n\nExclusion Criteria:\n\n1. History of peptic ulcer disease diagnosis or gastrointestinal bleeding within the past year. At screening, the history and findings of any EGD performed within the preceding 2 years were obtained by participant interview.\n2. Need for concomitant anticoagulant therapy (transient anticoagulation such as argatroban during the index admission is permitted, with randomization after it is stopped)\n3. Anticipated difficulty in undergoing gastrointestinal endoscopy during the study period.\n4. Use of a P-CAB, PPI, or H2-receptor antagonist within 1 week before randomization, or an active indication for these agents, a mucosal protectant, or an antacid at enrollment. Temporary use of these agents during acute care in the index admission, since discontinued and without a current indication, is not exclusionary.\n5. Hypersensitivity or contraindication to a P-CAB or to benzimidazoles.\n6. AST, ALT, ALP, or γ-GT ≥5 times the upper limit of normal (ULN), or total bilirubin ≥3 times the ULN at screening.\n7. Participation within the past 12 months in any of the following: (1) a clinical study that may affect the efficacy or safety assessments of the present study; (2) a study involving an investigational product or procedure not administered under standard-of-care guidelines; (3) a study that may pose additional risk to the participant. (Participation in other clinical studies is otherwise permitted.)\n8. Current use of, or use within five half-lives of, a contraindicated interacting drug (atazanavir, nelfinavir, rilpivirine, and preparations containing these components).\n9. Any other condition deemed by the investigators to render the patient unsuitable for study participation, including but not limited to:","19 Years",{"count":203,"type":22},1524,[152],"Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, no comparable guidance or evidence exists for stroke care. Tegoprazan is a potassium-competitive acid blocker offering rapid, meal-independent acid suppression with fewer drug interactions than proton pump inhibitors, yet whether it prevents such complications after stroke remains unknown. Thus, the investigators aim to evaluate whether tegoprazan reduces gastrointestinal complications in patients receiving antiplatelet therapy after ischemic stroke.\n\nTegoStroke is a phase 3, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at more than 20 centers in the Republic of Korea. Adult patients who are starting antiplatelet therapy after acute ischemic stroke or transient ischemic attack, and who are expected to continue it for at least 6 months, will be included. Eligible patients will be 1:1 randomized to receive oral tegoprazan 50 mg once daily or matching placebo for 180 days. The primary outcome is a composite of upper or indeterminate-origin gastrointestinal bleeding, gastric or duodenal ulcer ≥3 mm, or erosive esophagitis, ascertained up to a day-180 esophagogastroduodenoscopy. This study would provide the first randomized evidence on routine gastroprotection for patients on antiplatelet therapy after ischemic stroke.",[156,28,207,208,209,210],"Transient Ischemic Attack (TIA)","Cerebrovascular Disease","Gastrointestinal Complication","Gastrointestinal Bleeding",[209,212,213,156,214,208],"Gastroprotection","Gastrointestinal Gleeding","Transient Ischemic Attack","2026-07-07",{"date":217,"type":33},"2026-07-08",{"date":219,"type":33},"2026-01-26",{"date":221,"type":22},"2027-12",{"name":223,"class":40},"Hanyang University Guri Hospital",24,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100646442","clinical-efficacy-and-mechanism-research-of-getong-tongluo-capsule-in-ischemic-stroke-100646442","NCT07690020","Clinical Efficacy and Mechanism Research of Getong Tongluo Capsule in Ischemic Stroke","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form\n2. Aged between 18 and 80 years old\n3. Conform to the diagnosis of acute ischemic stroke referring to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023)\n4. Hospital admission within 21 days after disease onset\n\nExclusion Criteria:\n\n1. Patients with mild or no neurological deficits on admission: those with a score of 0 on the Modified Rankin Scale (mRS) at admission (defined as completely asymptomatic).\n2. Patients with severe baseline disability: those with a pre-stroke mRS score ≥ 3 (indicating moderate to severe disability requiring partial or full assistance with activities of daily living).\n3. Patients with transient ischemic attack, concomitant cerebral hemorrhage or subarachnoid hemorrhage; those complicated with brain tumor, Alzheimer's disease, psychiatric disorders, or suspected pre-stroke cognitive dysfunction.\n4. Patients complicated with severe cardiac diseases including valvular heart disease, infective endocarditis, myocardial infarction and heart failure; severe hepatic or renal insufficiency, respiratory failure, malignant tumors, or massive gastrointestinal hemorrhage.\n5. Patients who received any preparations containing the same active ingredients as the study drug (e.g., Pueraria lobata) within 2 weeks prior to stroke onset.\n6. Patients with a history of allergy to the study drug or preparations with identical active ingredients.\n7. Patients who received antibiotics within 1 month before onset; those taking probiotics or prebiotics long-term; patients with a past or in-hospital confirmed gastrointestinal disease history.\n8. Pregnant and lactating women.\n9. Patients deemed unsuitable for participation in this trial at the investigator's discretion.",{"count":232,"type":22},216,[71],"The purpose of this single-center, randomized, double-blind, controlled trial is to clarify the clinical efficacy and safety of Getong Tongluo Capsule in patients with ischemic stroke. Combined with gut microbiome and metabolomics techniques, investigators will explore whether this medicine exerts neuroprotective effects via the gut-brain axis. Investigators will further verify its pharmacological mechanism through animal experiments to provide evidence for its clinical application.",[28],[237,156,181],"Post-acute Ischemic Stroke",{"date":217,"type":33},{"date":105,"type":22},{"date":241,"type":22},"2030-01-31",{"name":243,"class":40},"Nanfang Hospital, Southern Medical University",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100543188","third-enhanced-control-of-hypertension-and-thrombectomy-stroke-domain-within-act-global-adaptive-platform-trial-100543188","NCT06352619","Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial","Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL_ENCHANTED3\u002FMT)","ENCHANTED3\u002FMT","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines;\n3. Sustained high systolic blood pressure ≥150 mmHg (2 readings \\\u003C10 mins apart) within 3 hours after completion of EVT.\n\nExclusion Criteria:\n\n1.Any definite contraindications to BP lowering treatment.",{"count":253,"type":22},2000,[71],"Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \\\u003C130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3\u002FMT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3\u002FMT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \\[≥180mmHg\\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \\[150-160mmHg\\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management.",[28],[258,259,156],"Blood Pressure","Endovascular Therapy","2026-07-06",{"date":217,"type":33},{"date":263,"type":33},"2024-10-11",{"date":265,"type":22},"2028-05",{"name":267,"class":40},"The George Institute",2,{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":83},"100643898","phase-3-intra-arterial-thrombolysis-for-acute-ischemic-stroke-with-medium-vessel-occlusion-100643898","NCT07668323","Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion： A Multicenter Prospective Randomized Controlled Clinical Trial","IAT-MEVO","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Time from symptom onset or last known well to randomization within 24 hours.\n* Clinical diagnosis of acute ischemic stroke confirmed by CTA or MRA as being caused by isolated acute medium vessel occlusion, including distal M2\u002FM3 segments of the middle cerebral artery, A2\u002FA3 segments of the anterior cerebral artery, or P1\u002FP2\u002FP3 segments of the posterior cerebral artery. Isolated occlusion is defined as a single symptomatic vessel occlusion; patients with multiple vessel occlusions or uncertain culprit vessel are excluded.\n* Baseline NIHSS score ≥ 6, or 3-5 with disabling deficits (e.g., motor weakness, aphasia, visual field defects), and NIHSS score ≤ 25 at the time of randomization.\n* For patients presenting beyond 6 hours from symptom onset: perfusion imaging criteria require Tmax \\> 6s volume ≥ 10 cc, and core infarct volume (defined as rCBF \\\u003C 30%) less than 50% of the Tmax \\> 6s volume.\n* Patient or legally authorized representative is able to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Clinical Exclusion Criteria:\n* Pre-stroke modified Rankin Scale (mRS) score \\> 2.\n* Presence of contraindications to intravenous thrombolysis.\n* Known allergy to heparin, contrast media, anesthetics, or other definite contraindications to endovascular treatment.\n* Comorbid severe diseases that may affect outcome assessment, including but not limited to malignancy, severe heart failure, or renal failure, with expected life expectancy \\\u003C 6 months.\n* Uncontrolled hypertension refractory to medical therapy (systolic blood pressure \\> 220 mmHg or diastolic blood pressure \\> 120 mmHg).\n* Baseline blood glucose \\\u003C 2.8 mmol\u002FL (50 mg\u002FdL) or \\> 22.2 mmol\u002FL (400 mg\u002FdL).\n* Known bleeding diathesis, including but not limited to: platelet count \\\u003C 100 × 10⁹\u002FL; heparin treatment within 48 hours with APTT ≥ 35 seconds; oral warfarin with INR \\> 3. Note: Patients without a history or suspicion of coagulation disorders do not require laboratory testing for coagulation parameters prior to enrollment.\n* Stroke onset with seizure or seizure occurring during the course of stroke, precluding accurate determination of baseline NIHSS score.\n* Female patients who are pregnant, lactating, or have a positive pregnancy test at hospital admission.\n* Currently participating in another investigational drug or device study that may interfere with the results of this study.\n* Other conditions judged by the investigator to be unsuitable for participation or posing significant risk to the patient.\n* Imaging Exclusion Criteria:\n* Intracranial hemorrhage confirmed by baseline head CT or MRI, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, or subdural\u002Fepidural hemorrhage.\n* Presence of midline shift or cerebral herniation, or other ventricular mass effect with midline shift.\n* Anticipated inability to complete endovascular treatment due to vascular tortuosity, severe vessel wall calcification, or other anatomical challenges.\n* Aortic dissection.\n* Multiple vessel occlusions confirmed by CTA or MRA with inability to identify the symptomatic culprit vessel, such as bilateral middle cerebral artery occlusion or concurrent middle cerebral artery and basilar artery occlusion.\n* Suspected or confirmed non-acute occlusion of the symptomatic culprit vessel.",{"count":278,"type":22},306,[152],"Study purpose:\n\nA multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) phase III trial is planned to evaluate the efficacy and safety of intra-arterial thrombolysis (IAT) in patients with acute ischemic stroke caused by medium vessel occlusion (MeVO), compared with best medical management alone.\n\nEligible participants (aged 18-80 years, baseline NIHSS score 6-25 or 3-5 with disabling deficits, confirmed MeVO within 24 hours of symptom onset) will be randomly assigned 1:1 to the intra-arterial thrombolysis plus best medical management group or the best medical management alone group.\n\nPrimary endpoint: proportion of patients with favorable functional outcome (modified Rankin Scale score 0-2) at 90±7 days post-randomization.\n\nSecondary endpoints:\n\n1. Recanalization rate (meTICI ≥ 2b) at 24±12 hours post-randomization;\n2. Early neurological improvement (NIHSS score change from baseline) at 7±1 days or discharge;\n3. Overall distribution of mRS scores at 90±7 days (shift analysis);\n4. Excellent functional outcome (mRS score 0-1) at 90±7 days;\n5. Health-related quality of life (EQ-5D-5L) at 90±7 days;\n6. Functional independence (Barthel Index score 95-100) at 90±7 days;\n7. Symptomatic intracranial hemorrhage (sICH) per Heidelberg criteria within 48 hours;\n8. Early neurological deterioration (NIHSS increase ≥ 4 points or any single item increase ≥ 2 points) within 7 days;\n9. Any intracranial hemorrhage within 48 hours;\n10. Procedure-related complications;\n11. All-cause mortality within 90±7 days.",[282,28],"Medium Vessel Occlusion",[284,285,286],"medium vessel occlusion","acute ischemic stroke","intra-arterial thrombolysis","2026-06-22",{"date":289,"type":33},"2026-06-25",{"date":291,"type":22},"2026-07-01",{"date":293,"type":22},"2029-08-31",{"name":295,"class":40},"The First Affiliated Hospital with Nanjing Medical University",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":324},"100523345","hospital-implementation-of-a-stroke-protocol-for-emergency-evaluation-and-disposition-100523345","NCT06094478","Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","HI-SPEED","Inclusion Criteria:\n\n* Age \\>=18 years\n* Final diagnosis: AIS, ICH, or SAH\n\nExclusion Criteria:\n\n* Final diagnosis: TIA or stroke NOS\n* Age \\\u003C18 years\n* Comfort care measures on day 0 or 1\n* Left hospital against medical advice\n* Enrolled in clinical trial related to stroke that is competing with this study",{"count":305,"type":22},900,[71],"Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The \"Door-In-Door-Out\" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US \"stand up\" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.",[96,28,309],"Hemorrhagic Stroke",[311,312,313,314],"interhospital transfer","quality improvement","implementation science","stroke systems of care","2026-05-18",{"date":317,"type":33},"2026-05-20",{"date":319,"type":33},"2024-10-17",{"date":321,"type":22},"2028-07-31",{"name":323,"class":40},"University of Chicago",8,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":336,"conditions":337,"keywords":341,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":354},"100507832","phase-2-post-thrombectomy-intra-arterial-tenecteplase-for-acute-management-of-non-retrievable-thrombus-and-no-reflow-in-emergent-stroke-100507832","NCT05892510","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)","Inclusion Criteria:\n\n* Adult participants (age≥18 years) presenting with ischemic stroke with arterial LVO on CT\u002FMR Angiogram of the intracranial internal carotid or middle cerebral artery (MCA) first segment (M1) or proximal second segment (M2) committed to thrombectomy using standard criteria within 24 hours of onset:\n* For 0-6 hours of symptom onset: Presence of arterial occlusion as defined above and ASPECTS≥3 on NCCT\n* For 6-24 hours of symptom onset: Additional imaging criteria on CTP or MRI perfusion of core volume \\\u003C100ml.\n* Qualifying CT\u002FMR within 4hrs of randomisation (repeat CT for transferred participants required if \\>4hr)\n* Pre-stroke Modified Rankin Scale (mRS) score of ≤2 (mild pre-existing disability permitted)\n* Local legal requirements for consent have been satisfied.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage identified by CT or MRI\n* ASPECTS 0-2 on NCCT\n* CTP or MRI perfusion ischemic core volume \\>100ml if presenting within 6-24 hours from symptoms onset\n* Anticipated endovascular stenting required for intracranial or extracranial atherosclerotic stenosis\u002Focclusion.\n* More than six retrieval attempts in the same vessel\n* Alteplase being infused within 30 minutes (\\~5x half-life) of anticipated trial drug administration\n* Contraindication to imaging with contrast agents\n* Any condition (eg.mid-arterial phase early venous filling) that in the judgment of investigators could impose hazards if study therapy is initiated\n* Pregnant women.\n* Current participation in another intervention research study that includes experimental interventions beyond standard-of-care.\n* Anticoagulation. INR ≤1.7 if on warfarin, and dabigatran reversal by idarucizumab are permitted.\n* Other standard contraindications to thrombolysis apart from time window.\n* Known terminal illness such that the participants would not be expected to survive a year.\n* Planned withdrawal of care or comfort care measures.",{"count":333,"type":22},462,[335,152],"PHASE2","Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b\u002F3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset.",[28,338,339,340],"Cerebrovascular Disorders","Brain Disorder","Central Nervous System Diseases",[342,343,344,345],"Tenecteplase","Fibrinolytic agents","Thrombectomy","No-reflow","2026-05-14",{"date":315,"type":33},{"date":349,"type":33},"2024-06-01",{"date":351,"type":22},"2027-11-30",{"name":353,"class":40},"University of Melbourne",12,{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":380},"100485384","brain-oscillation-synchronized-stimulation-to-enhance-motor-recovery-in-early-subacute-stroke-100485384","NCT05600374","Brain-Oscillation-Synchronized Stimulation to Enhance Motor Recovery in Early Subacute Stroke","Boss-Stroke","Inclusion Criteria:\n\nSubjects meeting all of the following criteria will be considered for admission to the trial:\n\n1. Age ≥ 18 years at the time of signing the informed consent.\n2. Cerebral ischemia identified by brain imaging (cerebral MRI or CT) occurred 1-14 days ago.\n3. Subject understands and voluntarily signs an informed consent document prior to any study related assessments\u002Fprocedures.\n4. Stroke has resulted in a new arm-\u002Fhand motor deficit with ≤ 50 points in the FMA-UE.\n5. Presence of motor evoked potentials (MEPs) in the paretic hand. MEPs has to be obtained in the resting muscle\n\n   o If no MEPs can be obtained, MEP search procedure can be repeated later up to 14 days after stroke onset.\n6. ● μ-oscillation (8-12 Hz) is recordable by EEG in the ipsilesional sensorimotor cortex with a sufficient signal-to-noise ratio of at least 3 dB\n7. ● Subject is able to adhere to the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\nSubjects presenting with any of the following criteria will not be included in the trial:\n\n1. Hemorrhagic stroke (this refers to primary intracerebral hemorrhage only; hemorrhagic transformation of ischemic infarcts is not an exclusion criterion)\n2. Estimated life expectancy \\\u003C 12 months\n3. Presence of intracranial ferromagnetic metal (extracranial stents ≥10 cm away from the TMS coil are acceptable) in accordance with current safety guidelines \\[18\\]\n4. Intraocular metal, cochlear implants\n5. If TMS might interact with sensors of active implants (e.g., intra-cardiac defibrillators).\n6. If a cranial bone gap affects currents induced by TMS (such as after craniotomy).\n7. History of seizures or epilepsy.\n8. Treatment intervention can't be started within 14 days after onset of stroke.\n9. Women during pregnancy and lactation.\n10. Participation in other studies if they are MDR or AMG studies or there is otherwise a high risk of insurance law issues intervening between two studies. In case of uncertainty, competing insurances must be contacted prior to participation\n11. persistent addiction disorder (except for nicotine dependence)\n12. CNS malignoma\n13. If there is any concern by the investigator regarding the safe participation of the subject in the study or for any other reason the investigator considers the subject inappropriate for participation in the study.\n14. The ability to consent for patients who are unable to speak will be assessed on the basis of the NIHS-Score by an independent physician (details see chapter 21 and appendix).",{"count":363,"type":22},144,[71],"We will investigate the therapeutic efficacy of EEG-synchronized noninvasive repetitive transcranial magnetic stimulation (rTMS) in the early subacute phase after ischemic stroke to improve upper limb motor rehabilitation. We hypothesize that synchronization of rTMS with the phase of the ongoing sensorimotor oscillation indicating high corticospinal excitability leads to significantly stronger improvement of paretic upper limb motor function than the same rTMS protocol non-synchronized to the ongoing sensorimotor oscillation or sham stimulation.",[28],[368,369,370,371],"Oscillation","motor recovery","Transcranial magnetic stimulation","EEG-synchronized",{"date":373,"type":33},"2026-05-15",{"date":375,"type":33},"2023-02-06",{"date":377,"type":22},"2028-02-28",{"name":379,"class":40},"University Hospital Tuebingen",4,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":405,"locationsCount":83},"100600015","phase-4-a-trial-of-edaravone-dexborneol-in-acute-ischemic-stroke-with-active-malignancy-100600015","NCT07091994","A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","PRECISE AM","Inclusion Criteria:\n\n* Age between 18 and 80 years (inclusive);\n* Diagnosis of acute ischemic stroke (AIS) according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke;\n* Time from symptom onset to enrollment ≤48 hours;\n* Presence of focal neurological deficits with a baseline NIHSS score of 4-24, and a combined score of ≥2 points on NIHSS Item 5 (upper limb motor) and Item 6 (lower limb motor);\n* Confirmed active malignancy before stroke onset or during hospitalization, defined as: Cancer diagnosed within 12 months prior to stroke, Presence of metastatic disease, Received cancer-directed therapy within the past 30 days, or Patients who declined cancer treatment (still considered active malignancy);\n* Signed informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Intracranial hemorrhagic diseases detected on head CT: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc;\n* Pre-stroke modified Rankin Scale (mRS) score \\>1;\n* Transient ischemic attack (TIA) as the current event;\n* Non-invasive skin cancers (e.g., basal cell carcinoma), primary central nervous system tumors, or hematologic malignancies;\n* Use of neuroprotective agents, including but not limited to: marketed edaravone, nimodipine, gangliosides, citicoline, piracetam, butylphthalide, human urinary kallidinogenase, or certain Chinese herbal medicines (see Concomitant Medications for details);\n* Patients with severe psychiatric disorders or dementia;\n* Hepatic or renal dysfunction: ALT or AST \\>3× upper limit of normal (ULN); Known liver diseases (e.g., acute\u002Fchronic active hepatitis, cirrhosis); Known kidney disease, renal insufficiency, serum creatinine \\>1.5×ULN, or creatinine clearance \\\u003C50 mL\u002Fmin;\n* Severe systemic diseases with an expected survival \\\u003C90 days;\n* Pre-stroke Eastern Cooperative Oncology Group (ECOG) performance status ≥3;\n* Hypersensitivity to edaravone, (+)-borneol, or any excipients;\n* Pregnancy, lactation, or planned pregnancy;\n* Participation in another clinical trial within 30 days prior to randomization or current enrollment in other interventional studies;\n* Any other condition deemed inappropriate for participation by the investigator.",{"count":363,"type":22},[25],"This multicenter randomized controlled trial aims to evaluate the efficacy and safety of edaravone dexborneol injection in patients with acute ischemic stroke (AIS) complicated by active malignancies. The study will primarily investigate whether this combined antioxidant and anti-inflammatory treatment can improve neurological functional recovery and assess its safety profile in this high-risk population. Investigators will compare outcomes between the edaravone dexborneol treatment group and a control group receiving standard therapy to determine if the intervention provides superior neuroprotective effects. Participants will receive the assigned treatment regimen, undergo serial neurological assessments and imaging studies to monitor stroke progression and recovery, and be closely followed for safety evaluations. The findings may offer evidence-based therapeutic options for managing this challenging clinical scenario where current treatment alternatives are limited.",[28,393],"Active Malignancies",[395,396,397,398],"active malignancies","ischemic stroke, acute","edaravone dexborneol","neuroprotection","2026-04-13",{"date":401,"type":33},"2026-04-16",{"date":105,"type":22},{"date":404,"type":22},"2026-12-31",{"name":243,"class":40},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":4},"100633800","phase-3-safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-acute-myocardial-injury-following-acute-ischemic-stroke-100633800","NCT07531394","Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex;\n2. AIS confirmed by neuroimaging within 72 hours of symptom onset (or last known well time);\n3. Acute myocardial injury confirmed by serial measurements of plasma cardiac troponin (cTn) within 72 hours of symptom onset \\[19\\];\n4. Written informed consent provided by the participant or their legal authorized representative.\n\nExclusion Criteria:\n\n1. Pre-stroke mRS score ≥ 2;\n2. AIS patients receiving intravenous thrombolysis or endovascular thrombectomy;\n3. Definite history of coronary heart disease, severe valvular heart disease, arrhythmia, heart failure, cardiomyopathy, elevated cTn, and abnormal electrocardiogram (ECG) before onset;\n4. Suspicious cardiac-related symptoms (recurrent\u002Fpersistent chest pain\u002Fchest tightness\u002Fpalpitations, etc.) within 14 days before the index stroke;\n5. Any disorder that could potentially lead to elevated pre-stroke cTn: sepsis, acute kidney injury, rhabdomyolysis, major cardiac surgery or myocardial infarction, previous ischemic or hemorrhagic stroke, congestive heart failure, pulmonary embolism, deep vein thrombosis, endocarditis, severe anemia, thyroid dysfunction, Drug application, etc.;\n6. Patients who are planning for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for the index AMI within 3 months;\n7. Severe liver or kidney dysfunction or malignant tumors;\n8. Uncontrolled hypertension (systolic blood pressure ≥ 200mmHg at enrollment despite medication);\n9. Any limb deformity, vascular or soft tissue injury, orthopedic trauma, or other conditions affecting the implementation of RIC;\n10. Pregnancy or lactation period;\n11. Patients with psychiatric disorders or other reasons unable to cooperate with treatment and follow-up.",{"count":413,"type":22},580,[152],"Introduction: The management of acute myocardial injury following acute ischemic stroke (AMI-AIS), a frequent complication that severely worsens prognosis, is challenging. Remote ischemic conditioning (RIC) has demonstrated therapeutic potential in separate cardiac and cerebrovascular diseases, and preliminary single-center evidence suggests its safety and efficacy in patients with acute ischemic stroke (AIS) complicating acute myocardial infarction. Therefore, we propose to conduct a multicenter, randomized controlled trial to definitively evaluate the safety and efficacy of RIC in patients with AMI-AIS.\n\nMethods: This is a multicenter, randomized, double-blind, sham-controlled trial of 580 participants with AMI-AIS. Participants will be randomized to receive either the RIC procedures or sham RIC procedures twice daily for 14 consecutive days. A 3-month follow-up will be conducted to assess the safety and efficacy of RIC in AMI-AIS patients. The primary study outcome is the incidence of major adverse cardio-cerebrovascular events (MACCEs). The secondary outcomes include mortality, neurological and cardiac function, cerebral infarct volume, and cerebral perfusion.",[28,417],"Myocardial Injury","2026-04-09",{"date":420,"type":33},"2026-04-15",{"date":422,"type":22},"2026-05-01",{"date":424,"type":22},"2028-12-01",{"name":426,"class":40},"Capital Medical University",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":83},"100565221","effects-of-transcranial-magnetic-stimulation-after-endovascular-treatment-for-acute-ischemic-stroke-100565221","NCT06639360","Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.\n2. Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1\u002FM2 segment of the middle cerebral artery.\n3. A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.\n4. Pre-stroke mRS score is ≤1.\n5. NIHSS score before thrombectomy is between 6 and 25.\n6. With vascular recanalization of mTICI \\> 2b\u002F3.\n7. Informed consent form signed.\n\nExclusion Criteria:\n\n1. Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.;\n2. Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys;\n3. Head CT\u002FMRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;\n4. Head CT\u002FMRI suggests acute cerebral infarction in both sides;\n5. Patients who are pregnant or breastfeeding;\n6. Patients with severe mental disorders or dementia who cannot cooperate with follow-up;\n7. Patients with other severe diseases resulting in an expected survival of less than 90 days;\n8. Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition;\n9. Patients who cannot cooperate with informed consent.",{"count":434,"type":22},60,[71],"This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.",[28,438],"Endovascular Thrombectomy","2025-11-26",{"date":441,"type":33},"2025-12-04",{"date":443,"type":33},"2025-08-02",{"date":404,"type":22},{"name":446,"class":40},"Xijing Hospital",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":454,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":83},"100571952","effect-of-exercise-gene-expression-and-histone-modifications-in-patients-with-hemiplegia-100571952","NCT06726941","Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia","Effect of Exercise on Neuroplasticity-Related Gene Expression and Histone Modifications in Patients With Hemiplegia","Inclusion Criteria:\n\n1. Participants who applied to Afyonkarahisar Health Sciences University Physical Therapy and Rehabilitation Clinic for rehabilitation purposes and had a stroke for the first time\n2. Participants with ischemia as the etiology of stroke\n3. Participants between the ages of 25-70\n4. Drugs that have been used for at least 1 month and up to 6 months after a cerebrovascular accident\n\nExclusion Criteria:\n\n1. Participants whose stroke etiology is other than ischemia\n2. Participants with clinically significant neurological disease other than stroke\n3. Participants with systemic and musculoskeletal diseases that will not tolerate neurological rehabilitation and prevent them from participating","25 Years","70 Years",{"count":457,"type":22},48,[71],"The aim of this study is to demonstrate the effect of routine exercise program on neuroplasticity through histone acetylation and gene expression changes in acute stroke survivors from an epigenetic perspective and to investigate the correlation of epigenetic effects with its effects on motor function and quality of life.",[28,461],"Acute Hemiparesis",[99,463,464],"acute hemiplegia","epigenetics","2025-11-22",{"date":467,"type":33},"2025-11-25",{"date":469,"type":33},"2024-12-20",{"date":471,"type":22},"2026-09-09",{"name":473,"class":40},"Afyonkarahisar Health Sciences University",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":483,"phases":4,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":4},"100611041","predictors-of-post-thrombectomy-cognitive-impairment-in-acute-ischemic-stroke-patients-100611041","NCT07235423","Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients","Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients : a Prospective Cohort Study","Inclusion Criteria:\n\n1. Adults (≥18 years).\n2. Acute ischemic stroke due to anterior circulation LVO confirmed by imaging undergoing EVT per guidelines.\n3. Successful reperfusion (mTICI 2b-3)\n4. Able to provide consent.\n\nExclusion Criteria:\n\n1. Severe aphasia\u002Fcoma interfering with cognitive assessment.\n2. Pre-existing dementia ( using Arabic version of the Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly).\n3. Non-ischemic etiology.\n4. Death within 72 hours.\n5. Refusal to participate in the study.",{"count":482,"type":22},120,"OBSERVATIONAL","This prospective cohort study investigates predictors of post-stroke cognitive impairment (PSCI) in patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion. Adult patients with successful reperfusion (mTICI 2b-3) will be followed at 3 and 6 months to assess cognition, functional recovery, and depression. Predictors across clinical, procedural, radiological, and laboratory domains will be analyzed. The study aims to identify risk factors for PSCI, estimate its prevalence, and evaluate its impact on outcomes.",[28],"2025-11-17",{"date":488,"type":33},"2025-11-19",{"date":490,"type":22},"2025-12-01",{"date":492,"type":22},"2028-01-15",{"name":494,"class":40},"Assiut University",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":511,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":83},"100443207","phase-2-co2-modulation-in-endovascular-thrombectomy-for-acute-ischemic-stroke-100443207","NCT05051397","CO2 Modulation in Endovascular Thrombectomy for Acute Ischemic Stroke","Evaluation of the Effect of Moderate and Controlled Hypercapnia on Ischemic Penumbra Vascular Collaterality During General Anesthesia for Anterior Circulation Acute Ischemic Stroke Mechanical Thrombectomy","COMET-AIS","Inclusion Criteria:\n\n• Large vessel occlusion anterior circulation stroke (terminal carotid artery and\u002For middle cerebral artery M1-M2 segment) eligible to mechanical thrombectomy under general anesthesia\n\nExclusion Criteria :\n\n* Active smoker\n* Chronic respiratory failure with ambulatory oxygen supplementation\n* Obesity with BMI\\>40Kg\u002F m2\n* Intubation before the procedure\n* Heart failure with intolerance to decubitus\n* Severe renal failure\n* Suspected elevated intracranial pressure\n* Pregnant or breastfeeding women",{"count":504,"type":22},50,[335],"Acute ischemic stroke due to large vessel occlusion is responsible of cerebral blood flow impairment with a progressive and extensive ischemic process. Cerebral collateral circulation may preserve an ischemic penumbra that could recover providing timely reperfusion of the occluded vessel. Mechanical thrombectomy is the standard of care for anterior circulation large vessel reperfusion. Strategy to promote cerebral blood flow in collateral circulation before reperfusion is scarce and rely mainly on blood pressure maintenance. Carbon dioxide is a potent cerebral vasodilator that could enhance collateral circulation blood flow and cerebral protection before reperfusion. General anesthesia with endotracheal mechanical ventilation could be used for thrombectomy and give the opportunity to modulate and control carbon dioxide tension in the blood. This study will test the effect of moderate hypercapnia on penumbral collateral circulation before reperfusion during mechanical thrombectomy for anterior circulation acute ischemic stroke under general anesthesia.",[28,344,508,509,510],"Anesthesia, General","Cerebrovascular Circulation","Carbon Dioxide",[512,513,514,515,516,517],"mechanical thrombectomy","large vessel occlusion stroke","carbon dioxide tension","cerebral blood flow","general anesthesia","cerebral collateral circulation","2025-09-30",{"date":520,"type":33},"2025-10-06",{"date":522,"type":33},"2022-07-20",{"date":524,"type":22},"2026-10-19",{"name":526,"class":40},"University Hospital, Clermont-Ferrand",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":535,"targetDuration":537,"studyType":483,"phases":4,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":4},"100607994","expansion-floating-craniotomy-for-the-treatment-of-malignant-cerebral-edema-caused-by-acute-ischemic-stroke-100607994","NCT07195786","Expansion-floating Craniotomy for the Treatment of Malignant Cerebral Edema Caused by Acute Ischemic Stroke","Expansion-floating Craniotomy for the Treatment of Malignant Cerebral Edema Caused by Acute Ischemic Stroke--A Prospective, Multicenter, Non-inferiority,Cohort Study（ECAIS）","ECAIS","Inclusion Criteria:\n\n* Age requirement: Adults aged \\>18 but \\\u003C80 years\n* Acute cerebral infarction diagnosis: Patients with internal carotid artery or middle cerebral artery occlusion within 48 hours, meeting all three criteria:\n\nNIHSS score ≥16 with item 1a (level of consciousness) ≥1 CT demonstrating \\>50% MCA territory infarction or hypoperfused area \\>2\u002F3, OR DWI hyperintensity volume \\>82 ml within 6 hours of onset, OR DWI infarct volume \\>145 ml within 14 hours\n\n* Imaging evidence: Midline shift ≥5 mm to the contralateral side on CT, OR significant ipsilateral ventricular compression with effacement of cerebral sulci\u002Fcisterns.\n\nExclusion Criteria:\n\n* Pre-stroke mRS score ≥1\n* Significant contralateral cerebral infarction\n* Symptomatic intracranial hemorrhage\n* Any known coagulopathy\n* Life expectancy \\\u003C3 years\n* Any severe comorbidities potentially interfering with treatment evaluation",{"count":536,"type":22},356,"3 Months","This clinical study investigates Expansion-floating Craniotomy (EC), a novel surgical technique for treating life-threatening malignant cerebral edema following large hemispheric infarction (commonly known as massive stroke). Malignant edema causes rapid increases in intracranial pressure, compressing vital brain structures and risking fatal brain herniation, requiring urgent intervention.\n\nThe current international standard treatment is traditional decompressive craniectomy (DC). DC involves removing a section of the skull to allow brain swelling, effectively reducing pressure and mortality risk. It is strongly recommended (Class I, Level A evidence) in major guidelines. However, DC typically requires a second major surgery (cranioplasty) approximately 3 months later to replace the removed bone flap, involving additional costs and risks like progressive intracranial hemorrhage or subdural hygroma.\n\nEC is a newer approach designed to potentially eliminate the need for a second surgery. During EC, surgeons use medical titanium plates to temporarily elevate the bone flap, creating immediate space for brain swelling while keeping the bone flap attached. Once brain swelling subsides (usually within weeks), a minor procedure flattens the titanium plates, allowing the patient's own bone to naturally reposition without requiring cranioplasty. EC may be performed based on surgeon assessment of brain swelling, guideline considerations, or experience. If EC is deemed unsuitable during surgery, DC will be performed instead.\n\nWhile early research suggests EC achieves decompression similar to DC while preserving the bone flap, its safety and effectiveness compared to the established DC procedure are not yet fully proven. DC is a well-understood, mature technique with known risks and benefits, including the certainty of needing cranioplasty. Conservative management is reserved for patients unfit for surgery but may not prevent neurological deterioration.This study aims to conduct a preliminary assessment of the outcomes of EC versus DC.",[28,75],[541,75,542,181],"Expansion-floating Craniotomy","decompressive craniectomy","2025-09-24",{"date":545,"type":33},"2025-09-29",{"date":547,"type":22},"2025-10-01",{"date":549,"type":22},"2027-05-30",{"name":551,"class":40},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":560,"enrollmentInfo":561,"targetDuration":4,"studyType":23,"phases":563,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":83},"100606445","methylprednisolone-sodium-succinate-with-endovascular-thrombectomy-for-large-ischemic-stroke-100606445","NCT07175649","Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke","Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke: A Randomized, Double-blind, Placebo-controlled Trial","PEARL-MERIT","Inclusion Criteria:\n\n* Aged 18 to 85 years;\n* Clinically diagnosed acute ischemic stroke with screening NIHSS ≥6;\n* Time from last known well to randomization ≤24 hours;\n* Pre-stroke mRS score of 0-1;\n* Occlusion of the responsible vessel confirmed by CT angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA) in intracranial segment of internal carotid artery (ICA), M1 or M2 segment of middle cerebral artery (MCA), and plan to undergo EVT;\n* Alberta Stroke Program Early CT Score (ASPECTS) of 0-5 on NCCT, or ischemic core volume ≥70 mL (defined as regional cerebral blood flow \\[rCBF\\] \\\u003C30% on CT perfusion \\[CTP\\] or apparent diffusion coefficient \\[ADC\\] \\\u003C620×10-⁶ mm²\u002Fs on MRI);\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage on NCCT or MRI;\n* Allergy to corticosteroids;\n* Allergy to contrast agents;\n* Severe infectious disease unsuitable for corticosteroid therapy or concurrent contraindications to corticosteroid treatment;\n* Random blood glucose \\>22.2 mmol\u002FL (400 mg\u002FdL);\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, use of warfarin with an international normalized ratio (INR) \\>1.7, or administration of novel oral anticoagulants within 48 hours of symptom onset;\n* Platelet count \\\u003C90×10⁹\u002FL;\n* History of gastrointestinal or urinary tract bleeding within the last month;\n* Current participation in another interventional clinical trial;\n* Pregnancy or lactating;\n* Renal dysfunction with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL);\n* Persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg despite antihypertensive treatment;\n* Life expectancy \\\u003C6 months due to terminal illnesses such as malignancy or severe cardiopulmonary disease;\n* Intracranial aneurysm or arteriovenous malformation;\n* Intracranial tumour with mass effect on imaging (except for small meningiomas);\n* Other conditions deemed unsuitable for study participation by the investigator, including inability to comprehend and\u002For comply with study procedures and\u002For follow-up due to psychiatric, cognitive, or emotional disorders.","85 Years",{"count":562,"type":22},912,[71],"It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vessel occlusion (LVO) patients with a large infarct core. In this study, the investigators hypothesize that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone in patients with evidence of a large infarct volume. The primary objective of the study is to establish the efficacy of methylprednisolone with EVT in patients with acute anterior circulation LVO and a large infarct core.",[28],"2025-09-09",{"date":568,"type":33},"2025-09-16",{"date":570,"type":22},"2025-10",{"date":572,"type":22},"2029-12",{"name":574,"class":40},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":483,"phases":4,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":83},"100521902","long-term-outcomes-of-laa-contrast-flow-in-ct-scans-after-endocardial-laa-closure-the-cf-ct-registry-100521902","NCT06075628","Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Long-Term Outcomes of Left Atrial Appendage Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Inclusion Criteria:\n\n* Subjects must be at least 18 years of age.\n* Subjects underwent LAA closure with Watchman\u002FWatchman FLX or Amplatzer Amulet at our institution from January 2019 till June 2022\n\nExclusion Criteria:\n\n* No definite exclusion criteria are defined for the study as all patients with Watchman-FLX or Amplatzer Amulet will be included in the study.",{"count":583,"type":22},100,"This study is intended to assess the incidence and correlation to the development of peri-device leaks (PDLs), device related thrombosis (DRTs) and cerebral vascular accident (CVA)\u002Ftransient ischemic attacks (TIAs) in association with left atrial appendage contrast flow (LAA-CF). It will be a multi-center, retrospective study. Approximately 100 subject charts will be reviewed.",[586,28],"Atrial Fibrillation","2025-08-27",{"date":589,"type":33},"2025-08-28",{"date":591,"type":33},"2023-07-24",{"date":593,"type":22},"2025-12",{"name":595,"class":40},"Kansas City Heart Rhythm Research Foundation",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":617,"completionDateStruct":618,"leadSponsor":620,"locationsCount":4},"100603997","phase-1-human-induced-neural-stem-cell-derived-exosomes-for-treating-acute-ischemic-stroke-100603997","NCT07143786","Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke","Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke: an Exploratory Clinical Trial","NSAIS","Inclusion Criteria:\n\n1. Aged 18-80 years (inclusive), regardless of gender;\n2. Clinically diagnosed with an anterior circulation ischemic stroke in the current episode, confirmed by head MRI\u002FCT, and able to receive the investigational product within 1 week after symptom onset;\n3. National Institutes of Health Stroke Scale (NIHSS) score of 6-20 (inclusive) at randomization, with NIHSS item Ia score \\\u003C2, and a change in NIHSS score from baseline to randomization of \\\u003C4 points;\n4. Female subjects of childbearing potential, or male subjects with partners of childbearing potential, must have no plans for pregnancy during the study and voluntarily use effective contraception;\n5. Modified Rankin Scale (mRS) score of 0 or 1 before the onset of the current stroke symptoms, as self-reported or reported by family members.\n6. All subjects, or their legal guardians, must provide written informed consent after receiving full information about the study and voluntarily participate in this clinical trial.\n\nExclusion Criteria:\n\n1. Those with epilepsy, Alzheimer's disease, Parkinson's disease, severe depression, or other neurological disorders or psychiatric illnesses that the investigator deems would impair their ability to participate in the trial or affect the assessment of the study;\n2. Patients who have experienced hemorrhagic transformation after the current ischemic stroke and are deemed unsuitable for participation in the clinical trial by the investigator;\n3. Patients with malignant tumors, except for those with low-grade malignant tumors such as basal cell carcinoma, papillary thyroid carcinoma, and localized prostate cancer in situ, who have received radical treatment for more than five years;\n4. Patients with severe infections, including sepsis, septic shock, severe pneumonia (refer to the 2007 criteria for severe pneumonia in adults by the Infectious Diseases Society of America\u002FAmerican Thoracic Society for the diagnosis of severe pneumonia);\n5. Patients with respiratory failure, or those with current evidence of pulmonary embolism or suspected pulmonary embolism;\n6. Patients whose organ function meets any one or more of the following criteria:\n\n   1. Absolute Neutrophil Count (ANC) \\\u003C 1.5 × 10⁹\u002FL, Platelets (PLT) \\\u003C 100 × 10⁹\u002FL;\n   2. Hemoglobin (Hb) \\\u003C 90 g\u002FL;\n   3. Aspartate Aminotransferase (AST) \\> 2.5 × Upper Limit of Normal (ULN) and\u002For Alanine Aminotransferase (ALT) \\> 2.5 × ULN, Total Serum Bilirubin (TBIL) \\> 1.5 × ULN;\n   4. Creatinine \\> 1.5 × ULN;\n   5. For patients not receiving anticoagulant or antithrombotic therapy: International Normalized Ratio (INR) \\> 1.7 or Activated Partial Thromboplastin Time (APTT) \\> 1.25 × ULN; for patients receiving anticoagulant or antithrombotic therapy: INR \\> 3.0 or APTT \\> 1.5 × ULN;\n7. Patients with a history of or current severe cardiovascular diseases:\n\n   1. Those with myocardial ischemia, myocardial infarction, or unstable angina pectoris graded above CTCAE (Common Terminology Criteria for Adverse Events) Grade II;\n   2. Severe arrhythmias deemed clinically significant by the investigator;\n   3. Cardiac insufficiency of NYHA (New York Heart Association) Class III-IV;\n   4. Those with other acute severe life-threatening complications;\n8. Patients with poorly controlled hypertension (defined as persistent systolic blood pressure \\> 220 mmHg or diastolic blood pressure \\> 120 mmHg despite antihypertensive treatment);\n9. Patients with poorly controlled diabetes mellitus (defined as blood glucose remaining \\> 16.8 mmol\u002FL despite treatment) or hypoglycemia (blood glucose \\\u003C 2.8 mmol\u002FL);\n10. Patients with a history of immunodeficiency, including: HIV-positive status, other acquired or congenital immunodeficiency diseases, idiopathic IgA deficiency, or those who have received systemic corticosteroid therapy (≥ 10 mg\u002Fday prednisone equivalent) or immunosuppressive drug therapy within 14 days prior to receiving the study drug, or who are expected to require such therapy during the trial;\n11. Patients positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) with positive HBV-DNA, positive Hepatitis C antibody (HCV), or positive Treponema pallidum antibody (TPAb\u002FRPR);\n12. Patients who have participated in other drug clinical trials within 3 months prior to screening;\n13. Patients with known allergies to the study drug or any of its components (e.g., human serum albumin);\n14. Patients unable to undergo cranial CT\u002FMRI examinations for any reason;\n15. Patients who have undergone major surgery, suffered severe trauma within 3 months prior to the first dose, or plan to undergo surgery that may affect neurological function assessment during the trial;\n16. Pregnant or lactating patients;\n17. Patients with other severe systemic diseases, or a history of any diseases or laboratory abnormalities that may confound study results, interfere with the subject's participation in study procedures, or are not in the subject's best interest to participate, and who are deemed unsuitable for enrollment by the investigator.",{"count":605,"type":22},38,[607,335],"PHASE1","A phase I\u002FIIa clinical trial investigating the safety and preliminary efficacy of intravenous administration of human induced neural stem cell-derived exosomes for acute ischemic stroke",[28],[611,612,285,613,614],"induced neural stem cell","exosome","safety","efficacy","2025-08-19",{"date":587,"type":33},{"date":547,"type":22},{"date":619,"type":22},"2027-12-31",{"name":621,"class":40},"Xuanwu Hospital, Beijing",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":646,"locationsCount":83},"100458246","phase-4-the-role-of-circadian-factors-in-regulation-of-neuroplasticity-in-ischemic-stroke-interventional-100458246","NCT05247125","The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional)","Inclusion Criteria:\n\n* acute (symptom onset to admission \\\u003C1 days) ischemic stroke\n* ischemic stroke affecting the branches of anterior cerebral artery, middle cerebral artery and posterior cerebral artery\n* age 18-80 years\n* moderate or severe stroke (National Institutes of Health Stroke Scale, NIHSS\\>=5)\n* intravascular stroke treatment with thrombolysis or thrombectomy leading to satisfactory reperfusion (if applicable)\n* informed consent\n\nExclusion Criteria:\n\n* secondary parenchymal hemorrhage (\\>hemorrhage index (HI)-2)\n* clinically unstable or life-threatening conditions\n* previous stroke in the last 6 months\n* known progressive neurological diseases\n* known psychiatric diseases\n* concomitant benzodiazepine medication\n* drug or alcohol abuse\n* pregnancy\n* inability to participate in the study\n* severe sensory aphasia\n* melatonin intake at\u002Fbefore admission\n* light therapy use at\u002Fbefore admission\n* blindness\n* severe sleep-disordered breathing (apnea-hypopnea index \\>=30\u002Fh)\n* contraindications to light therapy (severe retinopathy, epilepsy, porphyria, intake of drugs with photosensitizing effects)\n* contraindications to melatonin intake (severe bronchial asthma, severe autoimmune disorders, chronic kidney disease 3b stage and higher, leukosis)\n* congestive heart failure with reduced ejection fraction (\\\u003C=45%) or New York Heart Association (NYHA) classification III-IV functional class.",{"count":629,"type":22},80,[25],"There is a lack of complex studies which could establish the association between genetic circadian factors with the features and short-term outcomes of ischemic stroke, as well as the effects of various auxiliary therapies for circadian rhythm modulation for neuroplasticity enhancement and improvement of short-term outcomes in ischemic stroke.\n\nThe main research hypothesis is that circadian factors influence the recovery from ischemic stroke via sleep-mediated regulation of synaptic plasticity.\n\nThe project aims at the investigation of the influence of combined melatonin therapy and blue light exposure on molecular circadian biomarkers, sleep characteristics, neuroplasticity markers and stroke outcome in acute stroke patients.\n\nThis study is a prospective, interventional, randomized placebo-controlled trial.",[28,633],"Sleep Disorders, Circadian Rhythm",[635,636,637,638,639],"circadian misalignment","neuroplasticity","melatonin","light therapy","circadian disorder","2025-08-05",{"date":642,"type":33},"2025-08-08",{"date":644,"type":33},"2022-03-01",{"date":404,"type":22},{"name":647,"class":40},"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health"]